Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

February 29, 2008

Study Completion Date

October 31, 2008

Conditions
Colorectal Cancer
Interventions
DRUG

Irinotecan

Part 1: 125 mg/m\^2 IV infusion once a week on weeks 1 through 4 of each 6-week treatment cycle. Part 2: 180 mg/m\^2 IV infusion every other week until disease progression or unable to tolerate.

BIOLOGICAL

Panitumumab

Intravenous (IV) infusions of panitumumab 2.5 mg/kg once a week delivered in 6-week cycles.

DRUG

5-Fluorouracil

Part 1: IV bolus 500 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: IV bolus 400 mg/m\^2 and infusional 2400-3000 mg/m\^2 over 46 hours once every other week until disease progression or unable to tolerate.

DRUG

Leucovorin

Part 1: IV bolus 20 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m\^2 every other week until disease progression or unable to tolerate.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY